- Home
- GBR vs CPHI Comparison
GBR vs CPHI Comparison
Compare GBR & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBR
- CPHI
- Stock Information
- Founded
- GBR 1978
- CPHI N/A
- Country
- GBR United States
- CPHI China
- Employees
- GBR N/A
- CPHI N/A
- Industry
- GBR Oil & Gas Production
- CPHI Biotechnology: Pharmaceutical Preparations
- Sector
- GBR Energy
- CPHI Health Care
- Exchange
- GBR Nasdaq
- CPHI Nasdaq
- Market Cap
- GBR 5.2M
- CPHI 4.7M
- IPO Year
- GBR N/A
- CPHI N/A
- Fundamental
- Price
- GBR $1.01
- CPHI $1.95
- Analyst Decision
- GBR
- CPHI
- Analyst Count
- GBR 0
- CPHI 0
- Target Price
- GBR N/A
- CPHI N/A
- AVG Volume (30 Days)
- GBR 60.3K
- CPHI 26.1K
- Earning Date
- GBR 11-12-2025
- CPHI 11-12-2025
- Dividend Yield
- GBR N/A
- CPHI N/A
- EPS Growth
- GBR N/A
- CPHI N/A
- EPS
- GBR N/A
- CPHI N/A
- Revenue
- GBR $151,000.00
- CPHI $4,396,201.00
- Revenue This Year
- GBR N/A
- CPHI N/A
- Revenue Next Year
- GBR N/A
- CPHI N/A
- P/E Ratio
- GBR N/A
- CPHI N/A
- Revenue Growth
- GBR 4.14
- CPHI N/A
- 52 Week Low
- GBR $0.67
- CPHI $1.20
- 52 Week High
- GBR $1.78
- CPHI $3.35
- Technical
- Relative Strength Index (RSI)
- GBR 47.51
- CPHI 60.72
- Support Level
- GBR $1.00
- CPHI $1.85
- Resistance Level
- GBR $1.05
- CPHI $1.97
- Average True Range (ATR)
- GBR 0.05
- CPHI 0.11
- MACD
- GBR -0.01
- CPHI -0.01
- Stochastic Oscillator
- GBR 28.27
- CPHI 78.00
About GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.